FDA
-
-
-
-
-
-
-
Celcuity Inc. Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032
-
-
-
-
-
-
-
Celcuity Inc. Reports Release of First Quarter 2026 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Celcuity Announces Publication of Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Study of Gedatolisib Regimens in HR+/HER2- Advanced Breast Cancer in Journal of Clinical Oncology
-
-
-
-
-
-
-
Celcuity Presents Updated Results from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium
-
-
-
-
-
-
-
Celcuity to Initiate NDA Submission of Gedatolisib in PIK3CA Wild-Type Cohort in HR+/HER2- Advanced Breast Cancer Under FDA’s Real-Time Oncology Review Program
-
-
-
-
-
-
-
Stifel Reiterates Buy Rating on Celcuity Inc (CELC)
-
-
-
-
-
-
-
Celcuity Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update
-
326,362 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

